PMID- 10814731
OWN - NLM
STAT- MEDLINE
DCOM- 20000721
LR  - 20190614
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 865
IP  - 1
DP  - 2000 May 19
TI  - A novel neurotensin peptide analog given extracranially decreases food intake and 
      weight in rodents.
PG  - 35-44
AB  - Neurotensin decreases food intake in the rat when injected into the cerebral 
      ventricles. We tested the effect of a novel neurotensin analog (NT69L), injected 
      intra-peritoneally (i.p.), on weight gain and food intake in rats. Sprague-Dawley 
      rats (270 g) were injected i. p. with either saline or NT69L at 0.001 or 0.010 
      mg/kg. In further experiments, larger rats at a more steady state on the growth 
      curve (400 g) were injected with either saline or 0.010 or 1 mg/kg NT69L. Food 
      intake, water consumption and body weight were recorded daily. Weight gain was 
      significantly reduced in the smaller rats injected with 0.001 or 0.010 mg/kg, 
      showing only a 8.5 and 9.0% increase in original weight, respectively, as 
      compared to a 29% increase for the controls. The larger rats injected with 1 
      mg/kg, had a significant reduction in body weight with a 3.0% decrease in 
      original body weight as compared to a 2.4% increase for the controls. Food intake 
      was significantly reduced suggesting that the weight loss observed after 
      injection of NT69L was attributable in part to a reduction in food intake. The 
      genetically obese Zucker rats injected with NT69L (1 mg/kg) had a significant 
      reduction in weight gain and food intake. NT69L significantly increased blood 
      glucose and corticosterone levels and decreased TSH and T4 in Sprague-Dawley and 
      Zucker rats, an effect that was only transitory. NT69L also caused a decrease in 
      norepinephrine in both the hypothalamus and nucleus accumbens, and an increase in 
      dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and serotonin. In this study, 
      NT69L exhibited a consistent and dramatic effect on body weight and food intake 
      in Sprague-Dawley and obese Zucker rats, and enabled us to study the role that NT 
      plays in weight control and the functional interactions of NT with brain amines, 
      and metabolic and endocrinological parameters.
FAU - Boules, M
AU  - Boules M
AD  - Neuropsychopharmacology Laboratory, Mayo Foundation for Medical Education and 
      Research, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, 
      USA.
FAU - Cusack, B
AU  - Cusack B
FAU - Zhao, L
AU  - Zhao L
FAU - Fauq, A
AU  - Fauq A
FAU - McCormick, D J
AU  - McCormick DJ
FAU - Richelson, E
AU  - Richelson E
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Blood Glucose)
RN  - 0 (Peptide Fragments)
RN  - 0 (neurotensin 69L)
RN  - 333DO1RDJY (Serotonin)
RN  - 39379-15-2 (Neurotensin)
RN  - 9002-71-5 (Thyrotropin)
RN  - Q51BO43MG4 (Thyroxine)
RN  - VTD58H1Z2X (Dopamine)
RN  - W980KJ009P (Corticosterone)
SB  - IM
MH  - Animals
MH  - Blood Glucose/drug effects
MH  - Body Weight/*drug effects/physiology
MH  - Corticosterone/blood
MH  - Dopamine/blood
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Routes
MH  - Eating/*drug effects/physiology
MH  - Male
MH  - Neurotensin/*analogs & derivatives/*metabolism/pharmacology
MH  - Obesity/drug therapy/physiopathology
MH  - Peptide Fragments/*pharmacology
MH  - Pituitary Gland, Anterior/drug effects/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/blood
MH  - Thyrotropin/blood/drug effects
MH  - Thyroxine/blood/drug effects
MH  - Time Factors
EDAT- 2000/05/18 09:00
MHDA- 2000/08/01 11:00
CRDT- 2000/05/18 09:00
PHST- 2000/05/18 09:00 [pubmed]
PHST- 2000/08/01 11:00 [medline]
PHST- 2000/05/18 09:00 [entrez]
AID - S0006-8993(00)02187-9 [pii]
AID - 10.1016/s0006-8993(00)02187-9 [doi]
PST - ppublish
SO  - Brain Res. 2000 May 19;865(1):35-44. doi: 10.1016/s0006-8993(00)02187-9.